Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Anticorps > Biosimilaires

Anti-Human Claudin-18.2 Reference Antibody (Omectatug, RUO) (HX126256)

Anti-Human Claudin-18.2 Reference Antibody (Omectatug, RUO)
Anti-Human Claudin-18.2 Reference Antibody (Omectatug, RUO)
Prix(USD) :
Spécification :
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueHX126256
Description
omectatug (HX126256) is a research-grade recombinant antibody targeting CLDN18.2.
Highlights
  • ●Research Grade — For PK/PD studies, assay development, and ADA research.
Reactivité des espècesHuman
ApplicationsELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôteHuman
ClonalitéMonoclonal
IsotypeIgG1, Kappa
Cible CLDN18.2, Claudin-18.2
Niveau d'endotoxines < 10 EU/mg
Pureté >95% as determined by SDS-PAGE.
Numéro d'accès P56856-2
Forme Liquid
Tampon de stockage 0.01M PBS pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Expédition In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stabilité et stockage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs2867393-44-8
Contexte

Claudin-18 (CLDN18.2) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. CLDN18.2 is the therapeutic target of zolbetuximab (Vyloy).

Note For research use only. Not suitable for clinical or therapeutic use.
Images
  • Anti-Human Claudin-18.2 Reference Antibody (Omectatug, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade omectatug

Reférences
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs